Abstract
Overview
Introduction
Commercial Insight: Antidyslipidemics explores current trends and key future
issues in the management of dyslipidemia and the effects of generic
competition and healthcare reforms on the main drug classes in this market.
The growth potential of the leading classes is discussed, and case studies are
used to highlight possible strategies to maximize future growth for lipid
management franchises.
Scope
- Event-driven sales forecasts, for the period 2006-15, for the US, Japan,
France, Germany, Italy, Spain and the UK, along with a global overview
- Discussion of individual products in five main classes, focusing mainly on
the statins, fibrates and other antidyslipidemics (e.g. Zetia, Niaspan)
- Profiles of the country and market specific issues which will impact
future sales in the market including generic erosion and new product launches
- Commercial impact case studies on R&D innovation and the impact of generic
erosion
Highlights
2006 is likely to mark an inflexion point in the sales value of the statin
class across the seven major markets (7MM). Key drivers of this include patent
expiries to Zocor and Pravachol in the US, with a predicted $8 billion
expected to be wiped off the value of the branded statin monotherapy market
between 2006-11 as a result.
Strategies designed to blunt the impact of generic erosion on lipid management
franchises include the development and commercialization of novel products.
With further advances in LDL-C lowering efficacy unlikely, current research is
focused on developing better tolerated and more effective HDL-C targeted
therapies.
A growing in-licensing and acquisition trend has surfaced in lipid management
and antiatherosclerotic R&D. As in-house productivity falls, big pharma has
spent billions on shoring up product pipelines, focusing particular on novel
HDL-C targeted therapies, which Datamonitor believes is evolving into the new
battleground in lipid management.
Reasons to Purchase
- Gain insight into the antidyslipidemics market via up-to-date
thought-leader opinions and gold-standard IMS Health sales data
- Assess the potential impact of clinical trial results, generic erosion and
new product launches on the antidyslipidemics market
- Access independent, event-driven forecasts for key antidyslipidemic
products and classes across the seven major markets
| 
View Cart
